Loading…
Lobbying Spend
—
Filings
24
Firms Hired
1
Active Period
2007–2013
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Verifying Authority and Legality In Drug Compounding Act of 2012
2012 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 6584, Verifying Authority and Legality In Drug Compounding Act of 2012. H.R. 6638, S.A.F.E. Compounded Drugs Act of 2012.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 6584
S.A.F.E. Compounded Drugs Act of 2012
2012 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation has been introduced yet. H.R. 6584, Verifying Authority and Legality In Drug Compounding Act of 2012. H.R. 6638, S.A.F.E. Compounded Drugs Act of 2012.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 6638
To amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 3018
A bill to amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: S. 3274
To amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 3018
A bill to amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: S. 3274
To amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 3018
A bill to amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018 and S. 3274, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: S. 3274
To amend the Controlled Substances Act to address the use of intrathecal pumps.
2010 · first_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 3018
To amend the Controlled Substances Act to address the use of intrathecal pumps.
2009 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation introduced yet. H.R. 3018, To amend the Controlled Substances Act to address the use of intrathecal pumps. Amends the Controlled Substances Act to revise the definition of "dispense" to include the delivery of a controlled substance through the use of an intrathecal pump by a practitioner acting in the usual course of professional practice.
Client expense: — · Firm income: $11,250
Matched citations: H.R. 3018
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: H. Con. Res. 342
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: S. Con. Res. 88
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: H. Con. Res. 342
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $10,000
Matched citations: S. Con. Res. 88
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).
Client expense: — · Firm income: —
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).
Client expense: — · Firm income: —
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens. Support of H. Con. Res. 342 and S. Con. Res. 88, Expressing the sense of Congress that the Food and Drug Admin.'s new policy restricting women's access to medications containing estriol does not serve the public interest (intro. in House & Senate).
Client expense: — · Firm income: —
Matched citations: H. Con. Res. 342
Source: Senate LDA